Educational activities

Monthly International Seminar Series on Liver Toxicity and Steatotic Liver Disease and different EASL studio topics for DHILI will be organised at a later stage.

As a proposal within our educational activities, we will be launching from January a series of talks on Liver Toxicity and Steatotic Liver Disease, ONCE monthly, given by international experts in the field. The session outline would be a talk of around 45 min with 15 min left for discussion. Conferences will be held on the 3rd Wednesday of each month at 16.30h (CET) starting from January 17^th 2024.

These international seminar series are the result of an outstanding collaboration between the EASL DHILI Consortium (https://easldhiliconsortium.eu/) and the Halt-RONIN (UKRI-Horizon Europe) https://halt-ronin.com/

The objectives are:

• to improve collaboration between different group experts encompassing clinical investigators, researchers, basic scientists, industry partners and regulators.
• To foster scientific progress by disseminating the latest breakthroughs in research on hepatotoxicity and metabolic dysfunction-associated steatotic liver disease

This seminar explores the shift from identifying isolated molecular markers to understanding the integrated biological networks that drive Metabolic Dysfunction-Associated Steatotic Liver Disease. By synthesizing data across the genomic, transcriptomic, proteomic, and lipidomiclayers, the session will deconstruct how genetic susceptibility and metabolic flux converge to trigger lipotoxicity and disease progression. It is designed to attract a high-level scientific community of biochemists, systems biologists, hepatologists, and multi-omics researchers interested inthe mechanistic intersections of lipid metabolism, precision phenotyping, and the translation of complex datasets into targeted therapeuticinterventions. Silvia Sookoian, MD, PhD, is a Senior Research Scientist at CONICET, Head of Clinical and Molecular Hepatology, and Dean of Health Sciences at Maimonides University, Argentina. A graduate of the University of Buenos Aires, she is a physician-scientist dedicated to translating scientificdiscovery into clinical care. Her research focuses on the genetic, epigenetic, and molecular mechanisms driving the pathogenesis and progressionof metabolic dysfunction-associated steatotic liver disease (MASLD). Dr. Sookoian’s work bridges the gap between laboratory innovation andpatient-centered outcomes in the field of Hepatology.